tradingkey.logo

Dyadic International Inc

DYAI

1.000USD

-0.005-0.50%
Horarios del mercado ETCotizaciones retrasadas 15 min
30.11MCap. mercado
PérdidaP/E TTM

Dyadic International Inc

1.000

-0.005-0.50%
Más Datos de Dyadic International Inc Compañía
Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.
Información de la empresa
Símbolo de cotizaciónDYAI
Nombre de la empresaDyadic International Inc
Fecha de salida a bolsaNov 05, 2004
Director ejecutivoMr. Mark A. Emalfarb
Número de empleados6
Tipo de seguridadOrdinary Share
Fin del año fiscalNov 05
Dirección1044 North U.S. Highway One
CiudadJUPITER
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal33477
Teléfono15617438333
Sitio Webhttps://dyadic.com/
Símbolo de cotizaciónDYAI
Fecha de salida a bolsaNov 05, 2004
Director ejecutivoMr. Mark A. Emalfarb
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Mr. Jack L. Kaye, CPA
Mr. Jack L. Kaye, CPA
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Mark A. Emalfarb
Mr. Mark A. Emalfarb
Chief Executive Officer, Director
Chief Executive Officer, Director
4.73M
--
Ms. Ping Wang Rawson, CPA
Ms. Ping Wang Rawson, CPA
Chief Financial Officer
Chief Financial Officer
140.99K
--
Mr. Patrick K. Lucy
Mr. Patrick K. Lucy
Independent Chairman of the Board
Independent Chairman of the Board
50.76K
--
Dr. Ronen Tchelet, Ph.D.
Dr. Ronen Tchelet, Ph.D.
Vice President - Research and Business Development
Vice President - Research and Business Development
32.83K
+37.65%
Dr. Seth J. Herbst, M.D.
Dr. Seth J. Herbst, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph (Joe) Hazelton
Mr. Joseph (Joe) Hazelton
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Desglose de ingresos
Sin datos
Sin datos
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: mié., 25 de jun
Actualizado: mié., 25 de jun
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
Emalfarb (Mark A)
13.09%
Francisco Trust
9.44%
Bandera Partners LLC
4.34%
Chapin Davis Asset Management
2.44%
The Vanguard Group, Inc.
2.25%
Other
68.44%
Accionistas
Accionistas
Proporción
Emalfarb (Mark A)
13.09%
Francisco Trust
9.44%
Bandera Partners LLC
4.34%
Chapin Davis Asset Management
2.44%
The Vanguard Group, Inc.
2.25%
Other
68.44%
Tipos de accionistas
Accionistas
Proporción
Individual Investor
18.96%
Corporation
11.33%
Investment Advisor
9.46%
Investment Advisor/Hedge Fund
6.46%
Bank and Trust
0.87%
Hedge Fund
0.12%
Venture Capital
0.04%
Other
52.76%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
72
14.21M
47.24%
-54.21K
2025Q1
74
14.15M
47.29%
-44.89K
2024Q4
76
13.93M
47.30%
-33.37K
2024Q3
75
13.71M
46.92%
-360.61K
2024Q2
74
13.61M
46.61%
-301.69K
2024Q1
70
13.58M
46.69%
+53.57K
2023Q4
68
13.19M
45.91%
-223.07K
2023Q3
76
13.18M
46.01%
-549.63K
2023Q2
90
13.18M
46.01%
-1.13M
2023Q1
118
13.17M
45.97%
-1.38M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
Emalfarb (Mark A)
4.73M
15.72%
--
--
Apr 24, 2025
Francisco Trust
3.41M
11.33%
--
--
Apr 24, 2025
Bandera Partners LLC
1.57M
5.21%
--
--
Mar 31, 2025
Chapin Davis Asset Management
842.85K
2.8%
-25.45K
-2.93%
Mar 31, 2025
The Vanguard Group, Inc.
814.34K
2.71%
+8.54K
+1.06%
Mar 31, 2025
Tarnok (Michael P)
281.03K
0.93%
+10.78K
+3.99%
Jun 20, 2025
Geode Capital Management, L.L.C.
258.42K
0.86%
+18.25K
+7.60%
Mar 31, 2025
Northeast Financial Consultants Inc
250.00K
0.83%
--
--
Mar 31, 2025
Truist Bank
250.00K
0.83%
--
--
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
246.86K
0.82%
-969.00
-0.39%
Mar 31, 2025
Ver más
ETFs relacionados
Actualizado: sáb., 2 de ago
Actualizado: sáb., 2 de ago
Nombre
Proporción
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proporción0%
Dividendos
Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Sin datos
Fecha
Tipo
Relación
Sin datos
KeyAI